HiszpaniaA Phase 3 Randomized Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734™) in Participants with Moderate COVID-19 Compared to Standard of Care Treatment. EudraCT Number: 2020-000842-32, www.clinicaltrialsregister.eu, dostęp 2020-15-03.A Phase 3 Randomized Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734™) in Participants with Severe COVID-19 EudraCT Number: 2020-000841-15, www.clinicaltrialsregister.eu, dostęp 2020-15-03.TocilizumabAnhui, Chiny
Shaanxi, Chiny
Wielka Brytania, inneLopinawir + rytonawirWuhan, Chiny
Guangdong, Chiny
Hongkong
Uniwersytet Zhejiang, Chiny
Jiangxi, Chiny
Chongqing, Chiny
Hubei, Chiny
różne miasta
Syczuan, Chiny
Zhejiang, Chiny
Zhuhai, ChinyLopinawirZhejiang, ChinyASC09 + rytonawirUniwersytet Zhejiang, Chiny;